Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Peptide vaccination directed against IDO1-expressing immune cells elicits CD8+ and CD4+ T-cell-mediated antitumor immunity and enhanced anti-PD1 responses

1 Jul 2020

Abstract excerpt

Background The tryptophan-catabolizing enzyme indoleamine 2,3-dioxygenase 1 (IDO1), which subverts T-cell immunity at multiple levels, is itself subject to inherent T-cell reactivity. This intriguing deviation from central tolerance has been interpreted as counterbalancing IDO1-mediated immunosuppression. Based on this hypothesis, clinical studies employing an IDO1 peptide-based vaccine approach for cancer...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Cancer, Stress, Anesthesia, and Immune Response
Share to Tryptophan and brain disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32690770
DOI: 10.1136/jitc-2020-000605

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Peptide vaccination directed against IDO1-expressing immune cells elicits CD8+ and CD4+ T-cell-mediated antitumor immunity and enhanced anti-PD1 responsesPMID 32690770Read ↗

Caerin 1.1 and 1.9 peptides halt B16 melanoma metastatic tumours via expanding cDC1 and reprogramming tumour macrophagesSemantic proximity Read ↗

Indoleamine 2, 3-Dioxygenase 1 and CD8 Expression Profiling Revealed an Immunological Subtype of Colon Cancer With a Poor PrognosisSemantic proximity Read ↗

miR-448 targets IDO1 and regulates CD8+ T cell response in human colon cancerSemantic proximity Read ↗

The Targeting of Indoleamine 2,3 Dioxygenase ‐Mediated Immune Escape in CancerSemantic proximity Read ↗

A novel immunopeptidomic-based pipeline for the generation of personalized oncolytic cancer vaccinesSemantic proximity Read ↗

A novel immunopeptidomic-based pipeline for the generation of personalized oncolytic cancer vaccinesSemantic proximity Read ↗

CIITA-Driven MHC Class II Expressing Tumor Cells as Antigen Presenting Cell Performers: Toward the Construction of an Optimal Anti-tumor VaccineSemantic proximity Read ↗

Immune responses to a class II helper peptide epitope in patients with stage III/IV resected melanoma.Semantic proximity Read ↗

Clinical efficacy and immunity of a novel immune-modulatory peptide vaccine against IDO/PD-L1 (IO102/IO103) in combination with nivolumab in patients with metastatic melanomaSemantic proximity Read ↗

Natural CD4+ T-Cell Responses against Indoleamine 2,3-DioxygenaseSemantic proximity Read ↗

The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells.Semantic proximity Read ↗

The indoleamine 2,3 dioxygenase pathway drives intratumoral B cell maintenanceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.